Literature DB >> 17143079

Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders.

Charles B Pull1.   

Abstract

PURPOSE OF REVIEW: Both pharmacotherapy and cognitive-behavioural therapy are effective treatments for anxiety disorders. The present editorial reviews the current status of combination treatments with a focus on randomized controlled trials, meta-analyses and reviews that have been published in the past 3 years. RECENT
FINDINGS: Recent studies on treatments combining pharmacotherapy and cognitive-behavioural therapy for anxiety disorders have found little benefit for combination therapies versus monotherapies. New investigations have explored the potential benefits of sequential treatments versus the concomitant ones as well as the use of cognitive enhancers as adjuncts to psychotherapy.
SUMMARY: Uncertainty exists as to whether the combination of cognitive-behavioural therapy and pharmacotherapy in the treatment of anxiety disorders is associated with greater overall efficacy than with either treatment when given alone. New ways for combining the two types of treatments are being investigated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17143079     DOI: 10.1097/YCO.0b013e3280115e52

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  11 in total

1.  Mind over PMDD: A Glimpse into the Process of Pharmacotherapy-Psychotherapy Combination Treatment.

Authors:  Gili W Adler Nevo; Colman Nefsky
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2014-05

Review 2.  Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults.

Authors:  Janine V Olthuis; Margo C Watt; Kristen Bailey; Jill A Hayden; Sherry H Stewart
Journal:  Cochrane Database Syst Rev       Date:  2016-03-12

3.  Neural substrates for the distinct effects of presynaptic group III metabotropic glutamate receptors on extinction of contextual fear conditioning in mice.

Authors:  Alice Dobi; Simone B Sartori; Daniela Busti; Herman Van der Putten; Nicolas Singewald; Ryuichi Shigemoto; Francesco Ferraguti
Journal:  Neuropharmacology       Date:  2012-05-27       Impact factor: 5.250

Review 4.  Translating findings from basic fear research to clinical psychiatry in Puerto Rico.

Authors:  Gregory J Quirk; Karen G Martinez; Lelis L Nazario Rodríguez
Journal:  P R Health Sci J       Date:  2007-12       Impact factor: 0.705

Review 5.  Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.

Authors:  Jigna Rajesh Kumar; Ramamoorthy Rajkumar; Tharindunee Jayakody; Subhi Marwari; Jia Mei Hong; Sherie Ma; Andrew L Gundlach; Mitchell K P Lai; Gavin S Dawe
Journal:  Br J Pharmacol       Date:  2016-09-06       Impact factor: 8.739

6.  Enhancing dopaminergic signaling and histone acetylation promotes long-term rescue of deficient fear extinction.

Authors:  N Whittle; V Maurer; C Murphy; J Rainer; D Bindreither; M Hauschild; A Scharinger; M Oberhauser; T Keil; C Brehm; T Valovka; J Striessnig; N Singewald
Journal:  Transl Psychiatry       Date:  2016-12-06       Impact factor: 6.222

7.  TrkA-cholinergic signaling modulates fear encoding and extinction learning in PTSD-like behavior.

Authors:  Sudhirkumar Yanpallewar; Francesco Tomassoni-Ardori; Mary Ellen Palko; Zhenyi Hong; Erkan Kiris; Jodi Becker; Gianluca Fulgenzi; Lino Tessarollo
Journal:  Transl Psychiatry       Date:  2022-03-17       Impact factor: 6.222

8.  Impaired extinction of learned fear in rats selectively bred for high anxiety--evidence of altered neuronal processing in prefrontal-amygdala pathways.

Authors:  Patrik Muigg; Alfred Hetzenauer; Gabriele Hauer; Markus Hauschild; Stefano Gaburro; Elisabeth Frank; Rainer Landgraf; Nicolas Singewald
Journal:  Eur J Neurosci       Date:  2008-11-03       Impact factor: 3.386

9.  Pharmacotherapy of panic disorder.

Authors:  Charles B Pull; Cristian Damsa
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

Review 10.  HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand?

Authors:  Nigel Whittle; Nicolas Singewald
Journal:  Biochem Soc Trans       Date:  2014-04       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.